Jessica Fye
Stock Analyst at JP Morgan
(4.44)
# 279
Out of 5,172 analysts
216
Total ratings
60.74%
Success rate
14.28%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $17.70 | +69.49% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $20.17 | +28.90% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $33.51 | -25.40% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $11.81 | +94.75% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $180.62 | +10.18% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $63.43 | +2.48% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $51.38 | -51.34% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $89.27 | +34.42% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $312.17 | +51.52% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $17.41 | +336.53% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $90.78 | -1.96% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $54.13 | +119.84% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $221.43 | +19.23% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $454.00 | +16.74% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $275.28 | +39.86% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $70.99 | +12.69% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $35.57 | +46.19% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $88.51 | -13.00% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $28.15 | +24.33% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $136.00 | -0.74% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $524.28 | -37.06% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $9.70 | +34.02% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $29.91 | +67.17% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $28.68 | +4.60% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $72.22 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.19 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.55 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.49 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.74 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.56 | +348.72% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.62 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.51 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $17.70
Upside: +69.49%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $20.17
Upside: +28.90%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $33.51
Upside: -25.40%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $11.81
Upside: +94.75%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $180.62
Upside: +10.18%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $63.43
Upside: +2.48%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $51.38
Upside: -51.34%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $89.27
Upside: +34.42%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $312.17
Upside: +51.52%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $17.41
Upside: +336.53%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $90.78
Upside: -1.96%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $54.13
Upside: +119.84%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $221.43
Upside: +19.23%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $454.00
Upside: +16.74%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $275.28
Upside: +39.86%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $70.99
Upside: +12.69%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $35.57
Upside: +46.19%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $88.51
Upside: -13.00%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $28.15
Upside: +24.33%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $136.00
Upside: -0.74%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $524.28
Upside: -37.06%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.70
Upside: +34.02%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $29.91
Upside: +67.17%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $28.68
Upside: +4.60%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $72.22
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.19
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.55
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.49
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.74
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.56
Upside: +348.72%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $9.62
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $12.51
Upside: -